Introduction
Prospective epidemiological data have shown that an increased risk of cardiovascular disease is predicted by increments both in systolic and diastolic blood pressure. 1 This increase in risk is continuous and graded with no evidence of a J-shaped relationship. It is estimated that in middle-aged men, a 20 mm Hg higher systolic pressure is associated with a 60% increase in cardiovascular mortality, and with a 50% higher all-cause mortality over a 10-year period.
Prior to the introduction of drug therapy for severe hypertension, associated morbidity and mortality from stroke, coronary heart disease (CHD), congestive heart failure and renal failure were high. In the Mayo Clinic reports of 1939, 2 80% of hypertensive patients who developed papilloedema died within a year, 90% were dead within 2 years and few remained alive after 3 years. With the introduction of drug therapy, survival was dramatically improved; in an early study from the Hammersmith Hospital, 50% of treated patients survived 2 years. 3 The introduction of therapy changed not only the associated mortality rates, but also the relative importance of the causes of death, such that congestive heart failure and renal disease were virtually eliminated and stroke was no longer the main cause of death. The results of the Veterans Administration study laid to rest any doubts which may have existed about the advantages of treating moderate (diastolic blood pressure 105-114 mm Hg) and severe (diastolic blood pressure Ͼ115 mm Hg) levels of blood pressure. Drug treatment reduced strokes, heart failure, other cardiovascular and renal endpoints but not myocardial infarction. 4, 5 From this and other early trials a number of observations were made: a greater reduction in morbid events was seen among men compared with women and in the higher blood pressure groups at entry; the incidence of accelerated phase hypertension was greatly reduced by treatment; and older patients benefited more than the young.
On the whole, the limited number of participants in these early trials reduced their power to answer the question as to whether treated blood pressure reduced coronary events.
The benefits of treating hypertension have been extended to the larger population at risk from mild hypertension; this has been confirmed in several studies. In these patients it was particularly important to demonstrate that the advantages of blood pressure reduction were not counteracted by long-term adverse responses to the antihypertensive drugs. This assessment of risk:benefit ratio is particularly important in a group of patients for whom the individual attributable risk is relatively small.
In all the trials that have involved patients with mild hypertension, active treatment has conferred benefits when compared with placebo or, in the case of the Hypertension Detection and Follow-up Programme (HDFP) 6, 7 and the Multiple Risk Factor Intervention Trial (MRFIT), 8 the outcome in the special care group was better than in those patients who continued with 'usual' medical care.
In the Australian trial (entry diastolic pressures 95-109 mm Hg 9 ), active treatment reduced the incidence of stroke. Although fewer cases of fatal ischaemic heart disease occurred in the active treatment group, the numbers were small and the difference just failed to achieve statistical significance.
In the Medical Research Council (MRC) trial of mild hypertension (diastolic pressure 90-109 mm Hg), 10 stroke rate was again reduced by active treatment but there was no overall reduction in coronary events. The results of sub-group analysis from this trial require cautious interpretation. Comparing the two active regimens, the diuretic was more effective than the beta-blocker, propranolol, in reducing stroke rate. Strokes were reduced in both smokers and non-smokers by the diuretic, but only in non-smokers by propanolol. With the exception of non-smoking males, in whom a modest reduction in coronary events was associated with a beta-blocker, there was no effect of either treatment on coronary morbidity. When overall morbidity was assessed including silent infarcts diagnosed electrocardiographically, the beta-blocker group fared significantly better than the diuretic or placebo group. In the HDFP, which also included patients in the mild hypertension category, special treatment conferred additional benefits to usual care, both in respect of stroke prevention and coronary morbidity. However, because neither this study nor the MRFIT were placebo-controlled, no conclusive statement can be made about the definitive benefits of antihypertensive treatment. The International Prospective Prevention Study in Hypertension (IPPSH) 11 addressed the question of whether the incidence of cardiac and cerebrovascular events could be influenced by the inclusion in an antihypertensive regimen of a betablocker (oxprenolol), compared with treatment not containing a beta-blocker. No overall differences were found between treatment groups in total mortality, cardiac events or strokes. However, as in the MRC trial, subgroup analysis suggested that betablockers may confer some benefit in terms of a reduction in cardiac events in non-smoking men.
Another trial, the Heart Attack Primary Prevention Trial in Hypertension (HAPPHY), 12 also addressed the question of whether a beta-blocker-based regimen differed from the diuretic-based regimen with regard to the prevention of coronary artery disease in men with mild to moderate hypertension. The outcome of the trial was similar for the two groups and neither regimen preferentially reduced the incidence of hypertensive complications, including CHD. Further analysis failed to confirm the observations (from the MRC and IPPPSH studies) that non-smokers benefited from beta-blockers compared with diuretics with respect to coronary morbidity.
Patients in the HAPPHY trial received one of two beta-blockers, atenolol or metroprolol. Those receiving metopropol were followed for a slightly longer period and the data were analysed separately. 13 In the metopropol treated group overall mortality was lower than in the thiazide group because of fewer deaths from CHD and stroke. However, the number of endpoints was small in this sub-group analysis, so these data should be interpreted with caution.
Meta-analyses
In evaluating the potential benefits from drug treatment of hypertension, it is important to remember that individual trials were underpowered to detect differences in CHD outcome between drug and placebo, or between one drug and another. With the exception of stroke, for which the benefits of treatment are consistent, an apparently negative outcome with respect to CHD may be explained by insufficient power to detect a real difference if one exists.
MacMahon and colleagues 1 pooled data from a number of prospective observational studies ( Figure  1 ). Their analysis suggested that a prolonged reduction of 6 mm Hg in diastolic pressure would lead to 35-40% fewer strokes and 20-25% fewer coronary events. When the results of the intervention trials were pooled, 14 treatment was found to have reduced the risk of stroke by 38% and that of non-fatal myocardial infarction and CHD death by 16% ( Figure 2 ). Thus there was an apparent shortfall in benefit from drug treatment on risk of coronary disease (see below). The results of drug treatment in elderly patients with hypertension are generally consistent with the findings in younger subjects. However, because the absolute risks of CHD, stroke and heart failure associated with high blood pressure are much greater in older subjects, the potential benefits from treatment are considerably greater than in their younger counterparts.
The percentage reduction in the incidence of strokes in elderly hypertensive patients receiving drug treatment is similar to that seen in the young. [14] [15] [16] [17] [18] [19] [20] In at least two studies a significant reduction in cardiac mortality has also been observed and in two recent trials there has been a significant reduction in the incidence of coronary events. The cardiovascular benefits of therapy were also seen in a recent treatment trial of isolated systolic hypertension in the elderly. 18 In this study and in the MRC trial of treatment of older patients, 20 the reduction in coronary events appeared to be linked to therapy with a diuretic-based regimen. Whether there are indeed benefits in terms of coronary event outcome from diuretics as opposed to beta-blocker regimens remains uncertain.
The absolute benefits of active treatment of hypertension in reducing the incidence of cardiovascular events are difficult to determine from the trials. It is often stated, for example, based on the MRC trial report, that 850 mild hypertensive patients must be treated for 1 year to prevent one stroke. This estimate may grossly underestimate the benefits of treatment to ordinary hypertensives 21 for the following reasons. First, the ranges of blood pressure entry criteria in the MRC and Australian trials were 90-109 mm Hg and 95-109 mm Hg with mean entry levels of 98 and 100.4 mm Hg respectively. However, 'actual' mean blood pressures (those recorded a few weeks post-randomisation and on placebo) were 91 and 93 mm Hg. Presumably the benefits observed in the trials therefore relate to these lower actual blood pressure levels, and thus underestimate benefits which would accrue from lowering blood pressures which are genuinely maintained as high as 95 to 100 mm Hg. Secondly, the mortality rates in the controls in the MRC and Australian trials were low, in part because of the study exclusion criteria and the healthy volunteer effect, and most of the volunteers were middle class patients, who generally enjoy better cardiovascular health. Third, the intention-to-treat analyses make no allowance for the effects of a significant proportion of controls who received active antihypertensive medication. This inevitably leads to an underestimate of benefit. Furthermore, because treatment is more likely to be initiated in those controls with highest blood pressures (and hence at greatest risk) and those who stop active treatment are likely to be at least risk by virtue of their blood pressure levels, 'on treatment' analyses do not solve all these problems. Fourth, because inflexible drug regimens often using high dosages are inevitably fol- lowed in trials, side effects are likely to be more prevalent and severe (with implications for compliance) than in everyday clinical practice.
Trial data have also shown that, if left untreated, a significant number of mild hypertensives progress to more severe hypertension in a relatively short time, demonstrating the clear benefits of treatment in preventing the progression of hypertension.
These comments have not usually been incorporated into the often quoted evaluation of benefits in the treatment of mild hypertension but need to be borne in mind in considering the introduction of therapy into patients potentially at risk from hypertension-related cardiovascular disease.
During the last decade, physicians have been identifying unresolved issues in the treatment of Journal of Human Hypertension hypertension. Several key questions have been raised with regard to the long-term benefits of treatment with more contemporary drugs such as calcium channel blockers and ACE inhibitors. Moreover, the use of particular drugs in high risk patient sub-groups, eg diabetes, has not been systematically explored. In addition the level to which blood pressure should be lowered in hypertension remains uncertain.
The results of several large trials have been reported within the last few years, and after the meta-analysis published in 1994.
14 It is worrying that in attempting to address some of these key issues a less than critical approach has been directed to trial design, data analysis and interpretation. Even more worrying has been their uncritical acceptance and publication in widely read and highly cited medical journals.
Systolic Hypertension in Europe Trial
(Syst-Eur) 22 This was an important trial in two respects. It was designed to answer the question of whether drug treatment of isolated systolic hypertension (ISH) improves cardiovascular outcome. This trial was also the first prospective, randomised, placebo-controlled trial to evaluate a dihydropyridine calcium channel blocker-based regimen as first-line active treatment. During the earlier stages of this trial of 4695 patients, the results of a similar study in ISHthe SHEP trial, 18 were reported and clearly identified major cardiovascular benefits from the drug treatment of ISH, although in this case with a diuretic-based treatment regimen. The results of SHEP were conclusive, and in keeping with subgroup analyses of the MRC trial of the treatment of older patients, 20 confirmed reductions in cardiovascular events with diuretic-based treatment of older patients with ISH. On the basis of SHEP, some physicians questioned whether it was appropriate to continue Syst-Eur -an ethical issue that was vigorously defended by the investigators. Using a Bayesian approach to analysis they justified the continuation of Syst-Eur although in the construction of their 'prior hypothesis' it is likely that they did not include data from the MRC trial.
In the event, the continuation of Syst-Eur allowed an important additional question to be addressed in relation to calcium channel blocking drugs. Syst-Eur was stopped early by the Steering Committee because of unequivocal benefits from calcium channel blocker (CCB)-based active treatment -the magnitude of the benefit being at least as great as for other drug treatments in earlier trials -thus providing no credence to the much-publicised potential for harmful effects of CCBs reported in observational studies of treatment outcomes.
Recent sub-group analysis of Syst-Eur demonstrated substantial cardiovascular benefits in those patients with non-insulin dependent diabetes mellitus (NIDDM), another important result.
23
Hypertension Optimal Treatment Trial (HOT) 24 HOT was the first trial designed to evaluate how far blood pressure should be lowered and was a potentially important study in the light of concerns expressed about a possible J-shaped relationship between blood pressure lowering and cardiovascular risk. The trial design aimed for three target blood pressure groups in a randomised allocation of 18 790 patients with hypertension to р90, р85 and р80 mm Hg diastolic pressure. In the event the three randomised groups differed by only about 4 mm Hg diastolic pressure instead of the planned 10 mm Hg, and with the lower than expected cardiovascular incidence rate experienced, the trial was underpowered to answer the primary question. It would have been preferable early on in the trial, when it was discerned that there was inadequate separation of the groups, to consider re-randomising the 'middle' group to Ͻ90 or Ͻ80 mm Hg diastolic pressure. With greater differentiation of the groups there would have been a greater chance to test the original hypothesis. Regrettably the Steering Committee had to revert to 'on-treatment' analyses of the data, which are less robust because the benefits of the randomisation process are foregone. Even so, the reported nadir of blood pressure (138.5/82.6 mm Hg) associated with the fewest cardiovascular events was not convincingly substantiated by reference to the data provided (Figure 3) . HOT also addressed the question of potential benefits from aspirin in treated hypertensives. In this placebo controlled limb of the trial fewer cardiovascular events occurred in the active treatment group but these events were outnumbered by an excess of major gastro-intestinal bleeds, leading to the appropriate conclusion that the use of aspirin in hypertensive subjects should be restricted to sub-groups of hypertensive patients with controlled BP and at high risk of a future major cardiovascular event.
25
The United Kingdom Prospective Diabetes Study (UKPDS) 26 UKPDS was a long awaited study of the treatment of patients with non-insulin dependent diabetes (NIDDM). The blood pressure lowering limb of UKPDS evaluated macrovascular and microvascular endpoints as a function of different degrees of blood pressure lowering in 1148 hypertensive patients with NIDDM. There were unequivocal benefits associated with tight compared with less tight blood pressure control in terms of any diabetes-related endpoint (34%) and macrovascular outcomes (stroke reduction 44%, CHD reduction 31%). These benefits were significantly greater than those associated with greater or lesser improvements in HbA1C which did not impact significantly on macrovascular events. The benefits of greater blood pressure lowering in UKPDS is supported by a subgroup analysis of the HOT database and provides good evidence for making recommendations for lower target blood pressures in NIDDM. 25 A critical comment to be made about UKPDS concerns the investigators attempts to compare outcome in two treatment groups -one ACE inhibitor based and one beta-blocker based. 27 Here, in a randomised comparison of 400 patients allocated to captopril and 358 patients allocated to atenolol (a worrisome disparity) cardiovascular event rates were similar in the two groups. This is hardly surprising since this aspect of the study had negligible power to detect potentially important differences between the two groups. What is surprising is the uncritical way that the apparent 'equivalence' of treatment has been accepted both by diabetologists and indeed by the journals responsible for publishing the UKPDS results, where the obvious potential for a type 2 statistical error was not commented upon. 28 Although several trials incorporating ACE inhibitors as components of therapeutic regimens have demonstrated convincing benefits in the treatment of heart failure and left ventricular dysfunction, 29 and other studies suggest treatment benefits in sub-groups of patients with renal disease and Type I diabetes, 30 there had been no definitive trials of ACE inhibitors in hypertension. CAPPP attempted to address this question by comparing cardiovascular morbidity and mortality in hypertensive patients (n = 10985) randomised to treatment with either a captoprilbased regimen or 'usual' treatment (predominantly beta-blocker based). The primary outcome measure of cardiovascular morbidity and mortality was not influenced by particular treatments, but a number of secondary endpoints were differentially affected, eg, stroke incidence was higher in the captopril group. Regrettably this study was seriously flawed in two respects. Firstly, the randomisation was unbalanced, probably because the randomisation process (by sealed letter) gave the investigator the potential to influence the choice of treatment patients received. Thus, for example, there were more diabetic patients in those randomised to captopril. Secondly, blood pressure levels were higher throughout the trial in those randomised to the ACE inhibitor. This reflects the fact that up to two-thirds of the patients in the captopril group were given the drug once daily. Captopril needs to be given at least twice daily to provide adequate blood pressure control over 24 h, thus a large number of patients randomised to once daily captopril would have higher pressures during the latter half of the dosing interval and thus consequentially at greater risk of stroke. This study therefore could not help in addressing the all-important question of whether drugs that block the reninangiotensin system confer additional cardiovascular protection over conventional therapy.
The Captopril Primary Prevention Trial (CAPPP)

The Swedish Trial in Older Patients with Hypertension-2 (STOP 2) 31
STOP-2 was a further study designed to compare conventional drug treatment (thiazide ± betablocker) with a newer treatment, which in this case was either calcium channel blocker based or ACE inhibitor based. This study in older patients involved 6614 patients followed up for an average of 5 years. As with CAPPP, the design of this trial was based on an hypothesis that newer treatments would reduce cardiovascular mortality by 25% compared with older drugs, perhaps unrealistic given the former discussion and results of older trials. On all cardiovascular endpoints, including stroke, myocardial infarction and cardiovascular mortality, there was no significant difference in outcome when comparing newer drugs with conventional drugs, nor indeed were any significant differences observed when either ACE inhibitor-based treatment or calcium channel blocker-based treatment was compared with conventional drugs. One difficulty associated with interpreting these results however was the contamination across the three groups under investigation by the use of drugs from one of the competing limbs as add-on therapy. Furthermore this trial was underpowered to address the key question of differential effects of treatment regimens on CHD events -the endpoint round which controversy over differential drug effects is centred.
The Heart Outcomes Prevention Evaluation (The HOPE Trial) 32 Brief mention will be made here of this interesting trial, which although not in the strict sense a trial
Journal of Human Hypertension in hypertensive patients, was a trial designed to assess the role of an ACE inhibitor (ramipril) in patients at high risk for cardiovascular events. A total of 9297 high risk patients who had evidence of vascular disease or diabetes plus one other cardiovascular risk factor were randomly assigned to receive either ACE inhibitor or placebo for a 5-year follow up period. Ramipril reduced the rates of death from cardiovascular disease by 26% compared with placebo and a host of other cardiovascular endpoints was similarly reduced. The small differences in blood pressure between the two groups of approximately 3 mm Hg systolic have resulted in discussion and debate as to how much of the ACE inhibitor induced benefit could be blood pressure related. From the early meta-analyses of prospective observational studies and intervention trials, this difference in blood pressure might account for onethird of the benefit observed in the HOPE trial, however this may be an inappropriate comparison on account of the fact that the slope of the relationship between differences in blood pressure and cardiovascular outcome may be influenced by the presence or not of additional cardiovascular risk factors. This is clearly emphasised in several studies of high-risk patients where small differences in blood pressure have been associated with major differences in cardiovascular outcome. 24 Thus the final interpretation of the HOPE study in terms of the attribution of benefit to either blood pressure lowering or ACE inhibition remains unresolved.
The clear message from some of these trials of the 90's is that often crucial questions are being addressed by studies that contain critical flaws in design and data interpretation. Investigators involved in on-going studies in hypertension are urged to review critically aspects of their study design and plans for later analysis to avoid some of the problems outlined in this overview.
Trials in progress
From the above overview of the most recently-published trials it is apparent that the six major drug trials produced after the Collins meta-analysis, 14 have, with the exception of Syst-Eur, 23 not provided major definitive contributions to the information which was outstanding, following publication of the trials as meta-analysed in 1993 14 (Table 1) . It would be impossible for all the information outlined in Table 1 to be answered in individual ran- domised controlled trials for all drugs and all drug combinations in all sub-groups of patients. With this inevitable shortcoming of the likely available data, the WHO-ISH Blood Pressure Lowering Treatment Trialists' Collaboration was established and in 1998 they published a protocol for prospective collaborative overviews of major randomised trials of blood pressure-lowering treatments. 33 A registry of trials which satisfy various eligibility criteria (randomisation, at least 1000 patient years of follow up per limb, in progress after July 1995) was set up and initially included 30 trials. Since then a further seven trials have been added to the registry (Table  2 ). In addition to allowing an evaluation of the effects of the newer anithypertensive agents in subgroups of patients the meta-analyses of data will allow evaluation of the effects of agents on specific cardiovascular and non-cardiovascular endpoints (eg, ischaemic strokes, heart failure deaths or hospitalisations and major site-specific cancers) which individual trials are inevitably underpowered to investigate. The results of the initial meta-analyses of the data included in the WHO-ISH trialists registry will be presented in 2000 and a further round of analyses will take place in 2003. It is estimated that by 2003 data will be available on at least 270 000 patients with over a million patient years of follow-up. During that period it is expected that about 11 000 strokes and 16 500 CHD events will have occurred in the registry trials.
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Trials in progress: will they fill the gaps?
The only trial to assess the first question raised in Table 1 -on average, what is the optimal first-line agent-with head-to-head comparisons of three of the four major drug classes against the diuretic chlorthalidone is the ALLHAT trial which includes over 40 000 recruits. 34 The original design of ALLHAT is shown in Figure 4 . However in the year 2000, the doxazosin limb was withdrawn because of an increase in one of the secondary endpoints (heart failure) associated with the use of doxazosin, compared with the use of diuretic. 35 One key advantage of this trial is that it is, with one exception, 36 the only trial powered to compare effects of the agents involved on fatal and non-fatal coronary events. Given that there was an apparent shortfall in the benefits of blood pressure lowering on coronary events but not for stroke when trial results were compared with expectations from observational epidemiology, 1,14 coronary events is the critical primary endpoint to be evaluated.
A further major advantage of ALLHAT is that, by virtue of design and study size, meaningful analyses of sub-groups of patients such as diabetics, AfricanAmericans, and women, will be possible.
A disadvantage of ALLHAT is that because many patients will require more than one drug to reach study BP targets it was not possible to find a common add-on drug which would be equally effective for all four limbs of therapy. Hence a series of different and often outmoded drugs have been added into the first-line agents. This problem in design may result in differential BP lowering which could confound interpretation of differences in outcomes. Furthermore, should there be any positive or negative interaction between any of the add-on drugs and the first-line agents, this too could affect BP lowering and/or associated cardiovascular outcomes.
Only the ASCOT trial 36 was designed to address the question of what combination of drugs is most effective in preventing coronary events. This question is particularly important since earlier studies 24, 26 have shown that the majority of patients require at least two drugs to reach currently recommended targets. The design of ASCOT ( Figure 5 ) with its common third-line add on drug allows a direct comparison of the two drug combinations-the standard beta-blockers plus diuretic and the more contemporary calcium channel blocker plus ACE inhibitor.
ASCOT has the further advantage like ALLHAT that meaningful sub-group analyses will be feasible on important sub-groups such as diabetics since over 4000 diabetic patients with hypertension have been randomised into this trial.
Current recommendations for treating systolic blood pressure levels у140 mm Hg 25, 37 are not based
Journal of Human Hypertension on randomised trial evidence but several trials are in progress 33 using this systolic threshold as an entry criterion. Despite the limitations of the data, 38 the results of the HOT trial 24 were influential in determining the optimal target blood pressures as recommended in the 1999 BHS management guidelines. 25 However, whilst the HOT data are perhaps the best available they were, as discussed above, by no means definitive in determining the optimal diastolic target and even less robust for systolic targets. Further trials to answer these questions are required.
The issue of what, if any concomitant medications should be provided for hypertensive patients is being addressed in several trials. 33 The HOT trial provides guidance -incorporated in recent guidelines 25 -on aspirin use, and the HOPE trial has again emphasised the lack of cardiovascular benefits associated with the use of antioxidants. 32 Both the ALLHAT 34 and ASCOT 36 trials incorporate in a factorial design a robust evaluation of lipid lowering in hypertensive patients. In ALLHAT, patients with a low-density lipoprotein (LDL)-cholesterol in the range 120 to 189 mg/dl (100 to 129 mg/dl for those with known CHD) will be randomised to pravastatin or usual care. In the ASCOT trial (which unlike ALLHAT, excluded those with a history of CHD) patients with a total cholesterol р6.5 mmol/l were randomised to atorvastatin 10 mg or placebo. Both trials have sufficient power to evaluate impacts on all-cause mortality.
The HYVET trial 39 is unique in evaluating benefits of blood pressure lowering in those aged over 80, a group for whom the benefits of treatment are not fully established, and the SCOPE trial 40 will add supporting evidence since it includes those aged between 70 to 89. In addition, SCOPE will formally evaluate benefits for cognitive function associated with blood pressure lowering -which in view of the reduced rates of dementia observed among those treated with nitrendipine in the Syst-Eur trial 22 is potentially an important and exciting focus for intervention. The PROGRESS study 41 which is addressing the important and controversial question of blood pressure management post-stroke, will also supplement the available data on the very elderly since it has no upper age limit for entry.
Optimal antihypertensive therapy for patients with diabetes, renal impairment or both is controversial, although ACE inhibitors are currently recommended at least for Type I diabetes and proteinuria. 25, 37 The trial evidence regarding optimal therapy for blood pressure lowering for patients with diabetes is confusing and conflicting 24, 27, 28, 32 largely due to the shortcomings -particularly inadequate power -of the available trial data to date, all of which is based on subgroup analyses. However in addition to the large diabetic subgroups in ALLHAT and ASCOT already mentioned, several other studies 33 are comparing various drug classes in patients with diabetes and in one of these, the AASK trial 42 the benefits of more or less blood pressure lowering is addressed in a factorial design. Optimal blood pressure lowering therapy for patients with left ventricular hypertrophy has been evaluated in meta-analyses 43, 44 of large numbers of often rather
Journal of Human Hypertension inadequate studies which individually have produced conflicting data. From these meta-analyses it appears that ACE inhibitors and calcium channel blockers may have preferential effects on LV regression, at least over beta-blockers, but this impression is by no means established. The LIFE trial 45 is the first major study to compare the effects of two agents (a beta-blocker and an AIIA) among patients with LVH and hypertension.
Other trials needed
It is clear that assuming adequate power the blood pressure lowering trials in progress will contribute individually ( Table 2 ) and collectively 33 towards answering many of the outstanding questions relating to hypertension management. In the WHO-ISH hypertension management guidelines published in 1998 the authors identified a series of areas for future research (Table 3) .
It is apparent from Tables 2 and 3 that two issues remain unevaluated and to date no trials are attempting to investigate them. The first of these two issues is the optimal target for systolic blood pressure. Given that systolic is a better predictor of car- Hitherto two morbidity/mortality trials have been carried out in China 46, 47 and some underdeveloped countries have contributed patients to other hypertension trials. However with these exceptions, despite the increasing global problem of hypertension, most trial data hail from the developed Western world and no trials have been carried out purely in the developing world in, for example, black or south Asian hypertensive patients. Given ethnic dif-ferences in blood pressure responses for various antihypertensive agents, 48 the results of such trials may have major implications for the majority of the world's hypertensives who hail from such countries. Meanwhile the large Afro-Caribbean component randomised in the ALLHAT trial will provide some evidence regarding this sub-group, albeit in a Westernised setting.
34
Summary and conclusion
Few, if any, areas of medicine have as many large randomised trials to help guide practice as hypertension. Despite this, by the mid-1990s objective decisions on several key management issues could not be made on the basis of randomised trial evidence. Progress since that time has been limited, despite the publication of several major trials including tens of thousands of patients. However prospects for the future are more exciting with over 30 major trials in progress, and the potentially large advantages of a prospective collaboration among these trialists.
